Anti-CD79b ADCs with stable linkers regress tumors in multiple xenograft models. (A) The xenograft tumors of BJAB cells were allowed to grow to an average of 200 mm³ and then given a single dose intravenously of 50 μg or 16.6 μg of antibody-linked DM1 or MMAF/kg mouse. Unconjugated antibodies were dosed at 3.4 mg antibody/kg, equivalent to the highest amount of conjugated antibody. (B) Granta519 or (C) DoHH2 cell lines were treated as in panel A except that the drug doses were 100 μg or 33.3 μg conjugated DM1 or MMAF/kg mouse and the unconjugated antibody was dosed at 6.8 mg antibody/kg mouse. (D) The levels of surface CD79b expression on dissociated xenograft tumor cells and normal B cells as assayed by flow cytometry.